University Hospital Research (UHR)

The Hospital-University Health Research (RHU) program, financed by the French "Investissements d'Avenir" program, aims to boost the transfer of scientific innovations to the practice of care, by encouraging the establishment of a continuum between basic research and clinical research. By bringing together the academic, hospital and business sectors, RHU projects aim to improve patient care, enhance understanding of diseases and promote the emergence of more effective and better tolerated treatments.

Aix-Marseille University coordinates 3 RHU projects:

The EPINOV and PIONeeR projects are among the 10 RHU projects selected in France in 2017 (wave 3) and have a budget of €5.8M and €8.5M respectively, for a duration of 5 years.
The INNOV-CKD project is one of the 15 winners selected in 2019 (wave 4) and has a budget of 5.08M€ for 5 years.

EPINOV

Coordinated by Professor Fabrice Bartoloméi, this project focuses on the use of large-scale modeling of epileptogenic networks to guide surgical strategies. It consists of a multicenter trial involving 11 epilepsy surgery centers in France, using neuroinformatics technology for brain simulation developed by the researchers. This project involves five partners: AMU, INSERM, AP-HM, Hospices civils de Lyon and Dassault Systèmes.

For more information:


PIONeeR

Coordinated by Professor Fabrice Barlési, PIONeeR consists in evaluating the brakes in immunotherapy treatments for lung cancer. The consortium is made up of 9 partners: Aix-Marseille University, CNRS, Inserm, AP-HM, Institut Paoli-Calmettes, Centre Léon Bérard, and the companies AstraZeneca, Innate-Pharma, HalioDX, Imcheck Therapeutics.

This project aims to:

  • Decipher the complex mechanisms of resistance to immune checkpoint inhibiting antibodies;
  • Develop new therapeutic combinations;
  • Expand the range of immunomodulatory drugs in lung cancer;
  • Provide new diagnostic and therapeutic options for these patients.

Learn more about the project:

INNOV-CKD

Coordinated by Professor Laurent Bonello of the Cardiology Department of the Hôpital Nord (AP-HM), this project aims to develop innovative, automated methods that can be used in clinical practice to predict the individual risk of coronary complications in patients with chronic kidney disease. Acute coronary syndrome is the cause of myocardial infarction and affects 100,000 people in France and 800,000 in the United States each year. In 20 to 40% of cases, it affects patients with chronic renal failure. This project brings together recognized experts in vascular biology, nephrology and cardiology with leading manufacturers of innovative hemostasis tests.

The consortium is coordinated by Aix-Marseille University, the C2VN research unit (Inserm, INRAE, AMU), in partnership with the AP-HM and the industrial partners BioCytex and Stago.

To find out more, click here:

Contact information

Project manager

Transfer with the socio-economic and cultural world

PIONEER

Project leader

Scientific and technical manager

  • Fabrice Barlesi

Operational project manager

  • Marie Roumieux
  • Phone : +33 491384436
  • E-mail: marie.roumieux@univ-amu.fr

EPINOV

Project leader

Scientific and technical manager

  • Fabrice Bartolomei

Operational project manager

  • Aurélie Ponz
  • Phone : +33 4 91 38 49 34
  • E-mail: aurelie.ponz@univ-amu.fr

INNOV-CKD

Project leader

Scientific and technical manager

  • Laurent Bonello

Operational project manager

Keywords
research
clinic
health
patient
treatment
partnership